4.7 Review

Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.201006-0894CI

Keywords

idiopathic pulmonary fibrosis; survival; prognosis; predictors; clinical course

Funding

  1. CV Therapeutics
  2. Genzyme
  3. Gilead Science
  4. Nektar
  5. Actelion
  6. Amira
  7. Bayer
  8. Fibrogen
  9. NIH
  10. ASP/Chest Foundation
  11. Boehringer Ingelheim
  12. InterMune
  13. ImmuneWorks

Ask authors/readers for more resources

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available